Medication info
Gladiam Tablet 2 mg (Glimepiride)

Gladiam Tablet 2 mg (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Green rectangular tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200803973 · Notified 2008.04.11 · Insurance code 642105030

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, treatment should be started with 1 mg of glimepiride once daily. If necessary, the dose may be increased by 1 mg at intervals of 1–2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the requirement for this drug may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, changes in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this drug There is no precise dose equivalence between this drug and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this drug, it is advisable to follow the instructions under Initial dose. That is, start with 1 mg once daily and adjust the dose at intervals of 1–2 weeks. The potency and duration of action of the previously administered drug should be taken into account. 4) Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this drug, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate ingestion of sugar. Despite successful initial management of hypoglycemia during treatment with sulfonylureas, hypoglycemia may recur. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) is above 150 mg/dL. This drug is administered at 8 mg once daily with the first meal. Insulin is started at a low dose and increased at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, addition of metformin may be considered. Clinical information has been published on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to identify the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this drug is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication assists in blood sugar control for patients with type 2 diabetes by complementing dietary and exercise regimens. It can be used alone, and when oral hypoglycemic agents or insulin do not effectively control blood sugar, using this medication in combination can allow for more effective blood sugar management. Particularly, in cases where sufficient control is not achieved with sulfonylureas or metformin monotherapy, using this medication alongside metformin can enhance blood sugar improvement. Overall, this medication helps improve blood sugar control and manage diabetes more effectively.

How to take

Adult dose

1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, treatment should be started with 1 mg of glimepiride once daily. If necessary, the dose may be increased by 1 mg at intervals of 1–2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the requirement for this drug may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, changes in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this drug There is no precise dose equivalence between this drug and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this drug, it is advisable to follow the instructions under Initial dose. That is, start with 1 mg once daily and adjust the dose at intervals of 1–2 weeks. The potency and duration of action of the previously administered drug should be taken into account. 4) Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this drug, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate ingestion of sugar. Despite successful initial management of hypoglycemia during treatment with sulfonylureas, hypoglycemia may recur. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) is above 150 mg/dL. This drug is administered at 8 mg once daily with the first meal. Insulin is started at a low dose and increased at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, addition of metformin may be considered. Clinical information has been published on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to identify the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this drug is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or in a state of coma. Additionally, it is unsafe for individuals who have had allergic reactions to this medication or sulfonylureas. Patients with severely impaired liver or kidney function should not use this medication without prior experience with it, and transitioning to insulin therapy is recommended. Pregnant women, those who may become pregnant, or breastfeeding women should not take this medication. Insulin therapy is required in cases of severe infections or before and after surgery, trauma, and this medication should be avoided. In cases of gastrointestinal disorders such as diarrhea or vomiting, there is a risk of hypoglycemia due to inadequate nutrient absorption, so caution is required. During the first week of taking this medication, there is a heightened risk of hypoglycemia, and blood sugar levels should be carefully monitored. In particular, elderly persons, those with poor nutritional status, irregular eating patterns, or who do not balance exercise and carbohydrate intake may face increased risks of hypoglycemia. Individuals who consume alcohol frequently or have kidney or liver function issues, or who overdose on this medication, may also experience hypoglycemia, necessitating caution. Those with endocrine disorders such as thyroid dysfunction, pituitary dysfunction, or adrenal insufficiency are also at increased risk for hypoglycemia; careful monitoring of blood sugar is essential. While taking this medication, symptoms of hypoglycemia such as headaches, severe hunger, dizziness, drowsiness, confusion, blurred vision, sweating, and anxiety may occur, and immediate intake of sugar is required upon experiencing these symptoms. Temporary blurriness in vision may occur, and gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea may rarely present themselves. Serious side effects such as liver dysfunction or decreased blood cell count can occur rarely, so any unusual symptoms should be immediately discussed with a doctor. Allergic reactions leading to skin rash, hives, or difficulty breathing may occur; immediate treatment is necessary if such symptoms arise. In order to control blood sugar effectively, it is crucial to manage diet, exercise, and weight alongside taking this medication, and adherence to a regular dosing schedule is necessary. If hypoglycemia occurs, quickly consuming sugar or sweetened drinks can mitigate symptoms; thus, it is advisable to always keep some sugar handy. If taking other medications or starting new ones, it is essential to inform your doctor or pharmacist of potential interactions with this medication. In particular, caution should be taken when used in conjunction with beta blockers, certain antibiotics, and steroids, as they may cause significant fluctuations in blood sugar levels. For those who are pregnant or breastfeeding, insulin therapy is recommended instead of this medication to avoid harming the fetus or newborn. It is advisable not to use this medication in children under 18 years of age as its safety and efficacy have not been established. For elderly patients, dosage adjustment may be necessary due to decreased kidney function, and particular attention should be paid to the risk of hypoglycemia. If this medication is overdosed, severe hypoglycemia may occur, necessitating immediate emergency treatment, and blood sugar should be monitored continuously following a doctor's instructions.

Side effects

  • Hypoglycemia
  • headache
  • severe hunger
  • nausea
  • vomiting
  • fatigue
  • sleep
  • sleep disturbances
  • anxiety
  • aggressiveness
Show 68 more
  • decreased concentration
  • diminished agility or initiative
  • depression
  • confusion
  • speech abnormalities
  • aphasia
  • visual disturbances
  • tremors
  • incomplete paralysis
  • sensory disturbances
  • dizziness
  • weakness
  • loss of self-control
  • temporary mental confusion
  • cerebral convulsions
  • drowsiness
  • loss of consciousness
  • coma
  • shallow breathing
  • bradycardia
  • sweating
  • cool and clammy skin
  • tachycardia
  • hypertension
  • palpitations
  • angina
  • arrhythmia
  • blurred vision
  • fullness in the upper abdomen
  • pressure sensation
  • abdominal pain
  • diarrhea
  • increased liver enzymes
  • abnormal liver function
  • bile secretion disorders
  • jaundice
  • hepatitis
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • erythrocytopenia
  • granulocytopenia
  • agranulocytosis
  • pancytopenia
  • itching
  • urticaria
  • rash
  • dyspnea
  • hypotension
  • shock
  • anaphylaxis
  • angioedema
  • skin and mucous membrane syndrome
  • allergic vasculitis
  • photosensitivity reactions of the skin
  • decreased serum sodium concentration
  • taste disturbances
  • hair loss
  • weight gain
  • dizziness
  • abnormal liver function
  • abdominal pain
  • joint pain
  • indigestion
  • facial edema
  • erectile dysfunction
  • flushing of the face
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in an airtight container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Green rectangular tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.